← Leaderboards
Dennis R. Burton
Scripps Research Institute
$354,198,604
Attributed
$354,198,604
Total exposure
32
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $51M · FY2005–25$100M$75M$50M$25M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$485,706,901 · 33
By mechanism
UM1$429,617,951 · 5
R01$27,020,058 · 11
R37$12,169,893 · 2
P01$7,262,891 · 2
U01$4,759,450 · 2
U19$2,291,992 · 1
Top collaborators
No co-investigators on record.
Most similar at Scripps Research Institute
Same institution · by research overlap
- Carlos F Barbas$17,256,782
- Ann J Feeney$15,015,746
Others in their field
Top investigators on “Neutralizing Antibody”
- Barton F Haynes · Duke University$361,488,167
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$262,392,049
- Lawrence Corey · Fred Hutchinson Cancer Center$257,355,255
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$139,509,763
- Judith S. Currier · University Of California Los Angeles$139,509,763
Research focus
Neutralizing AntibodyAntibodiesDesignVaccinesAntigensInfectionResponseStructureVirusIn VivoBaseHiv VaccineEpitopesProgramsHiv InfectionsCellsAntibody FormationVaccine DesignAnimalsIn VitroAnimal ModelEngineeringImmunizationSpecificity
Grant awards (131)
Consortium for HIV/AIDS Vaccine Development$21,000,000
UM1 · FY2025 · AI · contact PI
Core P: Molecular and Cellular$343,762
P30 · FY2025 · AI · contact PI
Consortium for HIV/AIDS Vaccine Development$21,000,000
UM1 · FY2024 · AI · contact PI
Core P: Molecular and Cellular$597,927
P30 · FY2024 · AI · contact PI
Consortium for HIV/AIDS Vaccine Development$30,204,757
UM1 · FY2023 · AI · contact PI
Core P: Molecular and Cellular$685,299
P30 · FY2023 · AI · contact PI
Consortium for HIV/AIDS Vaccine Development$39,808,739
UM1 · FY2022 · AI · contact PI
Consortium for HIV/AIDS Vaccine Development$32,853,126
UM1 · FY2021 · AI · contact PI
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antivirals$635,619
UM1 · FY2021 · AI · contact PI
Consortium for HIV/AIDS Vaccine Development$33,346,203
UM1 · FY2020 · AI · contact PI
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antivirals$816,869
UM1 · FY2020 · AI · contact PI
Discovery of SARS-CoV-2 neutralizing Abs for therapy, prophylaxis and vaccine development.$188,714
UM1 · FY2020 · AI · contact PI
Consortium for HIV/AIDS Vaccine Development$20,999,714
UM1 · FY2019 · AI · contact PI
Consortium for HIV/AIDS Vaccine Development$733,872
UM1 · FY2019 · AI · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$12,037,011
UM1 · FY2018 · AI · contact PI
Operations and Management$7,963,923
UM1 · FY2018 · AI · contact PI
Development of immunology and immunization strategies that induce broadly pro$6,359,125
UM1 · FY2018 · AI · contact PI
Antibody Effector Function in Protection Against HIV-1$996,606
R37 · FY2018 · AI · contact PI
Genomic modification with purified nuclease proteins for HIV-1 therapy$779,593
R01 · FY2018 · DE · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$11,276,777
UM1 · FY2017 · AI · contact PI
Development of immunology and immunization strategies that induce broadly pro$8,028,634
UM1 · FY2017 · AI · contact PI
Operations and Management$1,912,696
UM1 · FY2017 · AI · contact PI
Antibody Effector Function in Protection Against HIV-1$996,606
R37 · FY2017 · AI · contact PI
Genomic modification with purified nuclease proteins for HIV-1 therapy$779,593
R01 · FY2017 · DE · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$27,313,077
UM1 · FY2016 · AI · contact PI
Development of immunology and immunization strategies that induce broadly pro$18,720,629
UM1 · FY2016 · AI · contact PI
Operations and Management$2,752,550
UM1 · FY2016 · AI · contact PI
Antibody Effector Function in Protection Against HIV-1$988,622
R37 · FY2016 · AI · contact PI
Genomic modification with purified nuclease proteins for HIV-1 therapy$779,593
R01 · FY2016 · DE · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$240,183
UM1 · FY2016 · AI · contact PI
Development of immunology and immunization strategies that induce broadly pro$240,183
UM1 · FY2016 · AI · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$23,224,392
UM1 · FY2015 · AI · contact PI
Development of immunology and immunization strategies that induce broadly pro$14,471,516
UM1 · FY2015 · AI · contact PI
Operations and Management$1,777,774
UM1 · FY2015 · AI · contact PI
Antibody Effector Function in Protection Against HIV-1$1,009,442
R37 · FY2015 · AI · contact PI
Genomic modification with purified nuclease proteins for HIV-1 therapy$792,592
R01 · FY2015 · DE · contact PI
Mechanisms of Antibody Interception of Virus Following SHIV Challenge$363,523
U19 · FY2015 · AI · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$19,555,822
UM1 · FY2014 · AI · contact PI
Development of immunology and immunization strategies that induce broadly pro$11,675,740
UM1 · FY2014 · AI · contact PI
Operations and Management$1,980,753
UM1 · FY2014 · AI · contact PI
Mechanisms of Antibody Interception of Virus Following SHIV Challenge$778,442
U19 · FY2014 · AI · contact PI
Antibody Effector Function in Protection Against HIV-1$635,370
R37 · FY2014 · AI · contact PI
Genomic modification with purified nuclease proteins for HIV-1 therapy$607,832
R01 · FY2014 · DE · contact PI
Multifunctional Human Anti-HIV Antibodies$473,750
R01 · FY2014 · AI · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$22,100,150
UM1 · FY2013 · AI · contact PI
Development of immunology and immunization strategies that induce broadly pro$14,054,524
UM1 · FY2013 · AI · contact PI
Operations and Management$1,320,484
UM1 · FY2013 · AI · contact PI
Antibody effector function in protection against HIV-1$883,126
R37 · FY2013 · AI · contact PI
Human Antibodies to HIV-1 by Repertoire Cloning$680,070
R01 · FY2013 · AI · contact PI
Probing the antibody response to HCV to facilitate rational immunogen design$593,616
R01 · FY2013 · AI · contact PI
Mechanisms of Antibody Interception of Virus Following SHIV Challenge$377,091
U19 · FY2013 · AI · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$15,760,885
UM1 · FY2012 · AI · contact PI
Development of immunology and immunization strategies that induce broadly pro$4,314,766
UM1 · FY2012 · AI · contact PI
Antibody effector function in protection against HIV-1$1,003,228
R37 · FY2012 · AI · contact PI
Operations and Management$948,744
UM1 · FY2012 · AI · contact PI
Human Antibodies to HIV-1 by Repertoire Cloning$706,835
R01 · FY2012 · AI · contact PI
Probing the germlines of broadly neutralizing anti-HIV antibodies in knockin mice$702,711
U01 · FY2012 · AI · contact PI
Probing the antibody response to HCV to facilitate rational immunogen design$621,118
R01 · FY2012 · AI · contact PI
Mechanisms of Antibody Interception of Virus Following SHIV Challenge$382,296
U19 · FY2012 · AI · contact PI
Antibody effector function in protection against HIV-1$1,087,698
R37 · FY2011 · AI · contact PI
Probing the germlines of broadly neutralizing anti-HIV antibodies in knockin mice$722,573
U01 · FY2011 · AI · contact PI
Human Antibodies to HIV-1 by Repertoire Cloning$698,488
R01 · FY2011 · AI · contact PI
Probing the antibody response to HCV to facilitate rational immunogen design$618,839
R01 · FY2011 · AI · contact PI
THE HUMAN ANTIBODY RESPONSE TO METAPNEUMOVIRUS: PROPHYLAXIS AND VACCINE DESIGN$519,049
R01 · FY2011 · AI · contact PI
Mechanisms of Antibody Interception of Virus Following SHIV Challenge$390,640
U19 · FY2011 · AI · contact PI
ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1$238,342
P51 · FY2011 · RR · contact PI
MUCOSAL SECRETION KINETICS OF THE PG9 BROADLY NEUTRALIZING ANTIBODY AGAINST HIV$13,093
P51 · FY2011 · RR · contact PI
Antibody effector function in protection against HIV-1$1,613,613
R37 · FY2010 · AI · contact PI
Human Antibodies to HIV-1 by Repertoire Cloning$760,703
R01 · FY2010 · AI · contact PI
Probing the germlines of broadly neutralizing anti-HIV antibodies in knockin mice$748,994
U01 · FY2010 · AI · contact PI
Probing the antibody response to HCV to facilitate rational immunogen design$614,982
R01 · FY2010 · AI · contact PI
THE HUMAN ANTIBODY RESPONSE TO METAPNEUMOVIRUS: PROPHYLAXIS AND VACCINE DESIGN$524,276
R01 · FY2010 · AI · contact PI
ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1$51,635
P51 · FY2010 · RR · contact PI
Molecular Studies on HIV Envelope for Vaccine Design$1,688,015
P01 · FY2009 · AI · contact PI
Probing the germlines of broadly neutralizing anti-HIV antibodies in knockin mice$757,589
U01 · FY2009 · AI · contact PI
Probing the antibody response to HCV to facilitate rational immunogen design$626,844
R01 · FY2009 · AI · contact PI
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING$615,059
R01 · FY2009 · AI · contact PI
THE HUMAN ANTIBODY RESPONSE TO METAPNEUMOVIRUS: PROPHYLAXIS AND VACCINE DESIGN$610,931
R01 · FY2009 · AI · contact PI
Antibody effector function in protection against HIV-1$532,354
R37 · FY2009 · AI · contact PI
Molecular Studies on HIV Envelope for Vaccine Design$1,944,381
P01 · FY2008 · AI · contact PI
Probing the germlines of broadly neutralizing anti-HIV antibodies in knockin mice$758,000
U01 · FY2008 · AI · contact PI
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING$597,974
R01 · FY2008 · AI · contact PI
THE HUMAN ANTIBODY RESPONSE TO METAPNEUMOVIRUS: PROPHYLAXIS AND VACCINE DESIGN$521,546
R01 · FY2008 · AI · contact PI
Identification of anti-scrapie drugs$373,734
P01 · FY2008 · AG · contact PI
Molecular Studies on HIV Envelope for Vaccine Design$1,284,298
P01 · FY2007 · AI · contact PI
ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1$659,165
R01 · FY2007 · AI · contact PI
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING$583,813
R01 · FY2007 · AI · contact PI
IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120$444,933
R01 · FY2007 · AI · contact PI
Identification of anti-scrapie drugs$391,516
P01 · FY2007 · AG · contact PI
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING$186,400
R01 · FY2007 · AI · contact PI
ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1$787,069
R01 · FY2006 · AI · contact PI
Molecular Studies on HIV Envelope for Vaccine Design$727,932
P01 · FY2006 · AI · contact PI
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING$585,783
R01 · FY2006 · AI · contact PI
IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120$458,223
R01 · FY2006 · AI · contact PI
Identification of anti-scrapie drugs$166,550
P01 · FY2006 · AG · contact PI
COOPERATIVE HUMORAL & CELLULAR IMMUNITY AGAINST HIV/SIV$163,288
P51 · FY2006 · RR · contact PI
COOPERATIVE HUMORAL &CELLULAR IMMUNITY AGAINST HIV/SIV$796,774
R01 · FY2005 · AI
ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1$787,723
R01 · FY2005 · AI
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING$505,278
R01 · FY2005 · AI
IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120$469,250
R01 · FY2005 · AI
Molecular Studies on HIV Envelope for Vaccine Design$353,365
P01 · FY2005 · AI
Identification of anti-scrapie drugs$166,550
P01 · FY2005 · AG
COOPERATIVE HUMORAL &CELLULAR IMMUNITY AGAINST HIV/SIV$45,973
P51 · FY2005 · RR
COOPERATIVE HUMORAL &CELLULAR IMMUNITY AGAINST HIV/SIV$776,662
R01 · FY2004 · AI
ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1$754,925
R01 · FY2004 · AI
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING$513,711
R37 · FY2004 · AI
IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120$469,250
R01 · FY2004 · AI
VIRAL EVASION AND HIV ENTRY-BLOCKING STRATEGIES$385,182
R01 · FY2004 · AI
NEUTRALIZING ANTIBODIES AGAINST ORTHOPOX VIRUSES$379,746
U01 · FY2004 · AI
THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS$310,275
R01 · FY2004 · AI
Identification of anti-scrapie drugs$166,550
P01 · FY2004 · AG
COOPERATIVE HUMORAL &CELLULAR IMMUNITY AGAINST HIV/SIV$150,572
P51 · FY2004 · RR
HUMAN ANTIBODIES TO INFECTIOUS AGENTS$2,964
M01 · FY2004 · RR
COOPERATIVE HUMORAL &CELLULAR IMMUNITY AGAINST HIV/SIV$774,821
R01 · FY2003 · AI
ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1$771,584
R01 · FY2003 · AI
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING$498,748
R37 · FY2003 · AI
NEUTRALIZING ANTIBODIES AGAINST ORTHOPOX VIRUSES$368,686
U01 · FY2003 · AI
THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS$310,275
R01 · FY2003 · AI
COOPERATIVE HUMORAL &CELLULAR IMMUNITY AGAINST HIV/SIV$698,992
R01 · FY2002 · AI
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING$484,222
R37 · FY2002 · AI
NEUTRALIZING ANTIBODIES AGAINST ORTHOPOX VIRUSES$321,151
U01 · FY2002 · AI
THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS$279,248
R01 · FY2002 · AI
HUMAN ANTIBODIES TO INFECTIOUS AGENTS$0
M01 · FY2002 · RR
ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPBL-SCID$555,600
R01 · FY2001 · HL
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING$470,120
R37 · FY2001 · AI
THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS$310,275
R01 · FY2001 · AI
ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPBL-SCID$525,000
R01 · FY2000 · HL
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING$456,427
R37 · FY2000 · AI
THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS$310,275
R01 · FY2000 · AI
CELLULAR/LIBRARY APPROACH--ANTIHIV NEUTRALIZING ABS$264,450
R21 · FY2000 · AI
HUMAN ANTIBODIES TO INFECTIOUS AGENTS$27,361
M01 · FY2000 · RR